Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...
Knock-down of the E3 ligase ITCH in fdAT2 organoids phenocopies a pathological surfactant protein C trafficking defect seen in a subset of individuals with familial pulmonary fibrosis ...
In addition, two days after infection, large amounts of virus were detected in the lungs and nasal turbinates ... This discovery indicates a new pathological mechanism of SARS-CoV-2 infection ...
OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a HER2 ...
Fibrosis progression can vary tremendously between different liver diseases and even among patients with the same disease. Risk factors for disease progression can be acquired or genetic and are ...
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...
Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis ... Canada Research Chair in Mechanisms of Health and ...
A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions. South ...
John Seymour, MBBS, FRACP, PhD, explains the mechanism of action of BCL-2 inhibitors like venetoclax. John Seymour, MBBS, FRACP, PhD, director of hematology at the Peter MacCallum Cancer Center and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback